ArriVent BioPharma, Inc.
Nasdaq · CIK 0001868279 · Fiscal year end 1231
Latest reported period: Latest published period
Operating Income
$-46.1M
Net Income
$-43.3M
Eps Basic
-0.96
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-46.1M | - | - |
| Net Income | $-43.3M | - | - |
| Eps Basic | -0.96 | - | - |
| Eps Diluted | -0.96 | - | - |
| Cash And Equivalents | $62.1M | - | - |
| Total Assets | $349.3M | - | - |
| Total Liabilities | $25.3M | - | - |
| Shareholders Equity | $324.0M | - | - |
| Operating Cash Flow | $-41.9M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | ArriVent BioPharma, Inc. | 2026-05-11 | 0001104659-26-058650 |
| 10-K | ArriVent BioPharma, Inc. | 2026-03-05 | 0001104659-26-024127 |
| 4 | ArriVent BioPharma, Inc. | 2026-02-03 | 0000902664-26-000675 |
| 10-Q | ArriVent BioPharma, Inc. | 2025-11-10 | 0001104659-25-108847 |
| 10-Q | ArriVent BioPharma, Inc. | 2025-08-11 | 0001558370-25-010975 |